Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world [1] . Sorafenib, an oral molecular-targeted drug, has become the standard therapy for advanced HCC (i.e., extrahepatic metastases, unresectable or not eligible for locoregional therapy) [2] . Sorafenib is a multiple kinase inhibitor which affects tumor proliferation and angiogenesis by inhibiting Raf-1, B-Raf kinase, vascular endothelial growth factor receptor 1, 2 and 3, platelet-derived growth factor receptor β, Flt-3 and c-KIT 2.
Two recent double-blind randomized phase III trials, the Sorafenib HCC Randomized Protocol (SHARP) [2] and the Asian-Pacific Trial [3] , have shown improvement in overall survival after sorafenib treatment; in addition, sorafenib is believed to be particularly effective for distant metastasis. However, the partial response was low at 2-5%, and there were no cases of complete response (CR) among the 449 patients treated with sorafenib in these trials. Therefore, sorafenib has been considered as a disease stabilizer.
Herein, we report a very rare case treated with sorafenib for HCC with multiple lung metastases resulting in a CR that has been maintained for 48 months.
Case Report
A 77-year-old Japanese female was diagnosed with chronic hepatitis C in 1990. A HCC (13 × 10 mm) was detected in segment 7/8 on a computed tomography (CT) scan and treated with percutaneous ethanol injection therapy in April 2007. Subsequently, recurrence of the HCC (23 × 13 mm) was observed in December 2010 in the same segment, and microwave coagulation therapy was performed. In April 2011, a chest X-ray image and CT scan revealed multiple lung metastases ( fig. 1a) . No brain or bone metastases could be detected.
Laboratory test results at the time of diagnosis were as follows: albumin 2.9 g/dl, aspartate aminotransferase 30 IU/l, alanine aminotransferase 15 IU/l, total bilirubin 0.5 mg/dl and prothrombin international normalized ratio 1.05. The patient had good reserve liver function with a Child-Pugh score of 6 (Child-Pugh class A) and did not have any ascites or findings of encephalopathy. Tumor markers such as α-fetoprotein (AFP; 76,170 ng/ml), the lens culinaris agglutinin-reactive fraction of AFP (7.5%) and des-γ-carboxyprothrombin (DCP; 63,400 mAU/ml) were elevated. Sorafenib administration was initiated at a reduced dose of 400 mg/day, because of the patient's advanced age and low body mass index (BMI) of 19.7.
After 4 months of sorafenib administration, the tumor markers decreased to normal levels (AFP 7.5 ng/ml, DCP 30 mAU/ml), and the metastatic lung lesions had disappeared ( fig. 1b) . We considered that the patient had achieved a CR according to the RECIST evaluation. The patient continues to be treated with sorafenib at a reduced dose of 400 mg/day without adverse effects and is still maintaining a CR.
Discussion
The present patient represents a rare case involving multiple lung metastases, confirmed on the basis of imaging and tumor marker levels, who achieved a CR after treatment with sorafenib. Furthermore, it was unusual because the patient has maintained this CR for 48 months and has continued sorafenib treatment without adverse effects. There are 2 im- Sorafenib is usually used for disease stabilization, and its response rate is <9%. In a retrospective study that compared sorafenib responders (CR and partial response) and nonresponders (stable disease, progressive disease and nonprogressive disease), multiple lung metastases were frequently observed in responders to sorafenib [4] . Therefore, sorafenib seems to be effective in the treatment of extrahepatic metastasis, especially lung metastasis. Shiba et al. [5] reported that significant factors in their 18 Japanese cases involving a CR were sex (female), low body weight (<59 kg), early clinical stage and use of a small initial dose. The clinical characteristics of the 12 reported cases and our case that achieved a CR as a result of sorafenib treatment are detailed in table 1 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . There were 6 (46%) lung metastasis cases. The data suggest that sorafenib is useful in the treatment of lung metastasis. Intrahepatic tumor stage seems unrelated to the rate of CR, because 8 out of 13 cases were at stage T3-4. AFP levels decreased by >20% in all cases presented in table 1, but 9 out of 13 cases had an initial AFP level of ≥400 ng/dl. This indicates that the AFP response is a good prognostic factor regarding CR and also that it is possible to achieve a CR regardless of the initial AFP levels.
The number of males and females was 11 and 2, respectively. Interestingly, only 4 out of 13 cases had commenced treatment with sorafenib at a dose of 400 mg/day (table 1) . Elucidation of the characteristics of HCC patients who attained a CR after sorafenib treatment allows prediction of efficacy and survival outcome before the initiation of treatment. However, populations of patients who have achieved a CR are too small for definitive conclusions to be made. Further evaluation in future clinical studies is required.
Five out of 13 cases had maintained a CR for >10 months (table 1) . Two among these 5 cases exhibited multiple lung metastases. These findings suggest that a patient who has multiple lung metastases can be expected to achieve a long-term CR. It has been controversial as to whether or not sorafenib treatment should be continued after the diagnosis of a CR. In a previous study, 188 patients who had undergone sorafenib monotherapy were analyzed, and it was reported that patients who received sorafenib for >90 days showed a favorable outcome [18] . In fact, 3 out of 5 long-term CR patients detailed in table 1 continued sorafenib administration. Consequently, continuation of sorafenib treatment may be important in maintaining a long-term CR. The tolerability of sorafenib must be a limitation regarding continuation of the treatment. Actually, in most patients, the initial dose of sorafenib had been reduced because of adverse effects (table 1). In the GIDEON study [19] , the advantage of using a sorafenib dose of 800 mg/day had been demonstrated. However, a randomized control study carried out by the SOraFenib Italian Assessment (SOFIA) group compared initial doses of 400 mg/day and 800 mg/day. It was found that the therapy group that received the lower dose of 400 mg/day had a longer median survival time [20] . In our case, we started sorafenib treatment at a reduced dose of 400 mg/day because the patient was elderly and had a low BMI. As mentioned, the patient has been maintained on the same dose for >3 years without adverse effects.
In conclusion, multiple lung metastases and low body weight seem to be the characteristics required for the achievement of a long-term CR. The reason for the superiority regarding the use of a reduced initial dose of 400 mg/day remains unclear. However, our case suggests the possibility of achieving a long-term CR as a result of continuation of treatment with this dose of sorafenib. The limitation of this report is that the periods over which a CR was sustained in the cases detailed in table 1 might be underestimates; this is because many of the patients would have continued to maintain their CR after the date on which their data were Fig. 1 . Chest CT images. a CT image at the initiation of sorafenib administration. Innumerable multiple lung metastases were revealed in both lungs. b CT image 4 months after sorafenib treatment. The multiple lung metastases disappeared in both lungs after sorafenib treatment.
